EGFR and non-small cell lung carcinoma: This study highlights the importance of performing a rebiopsy to detect the T790M mutation in patients with EGFR-mutated NSCLC with disease progression after first- or second-generation EGFR-TKI, allowing a greater number of patients to benefit from sequential treatment with osimertinib.